Neuron-Type Specific Loss of CDKL5 Leads to Alterations in mTOR Signaling and Synaptic Markers
CDKL5 disorder is a devastating neurodevelopmental disorder associated with epilepsy, developmental retardation, autism, and related phenotypes. Mutations in the CDKL5 gene, encoding CDKL5, have been identified in this disorder. CDKL5 is a protein with homology to the serine-threonine kinases and incompletely characterized function. We generated and validated a murine model bearing a floxed allele of CDKL5 and polyclonal antibodies to CDKL5. CDKL5 is well expressed in the cortex, hippocampus, and striatum, localized to synaptosomes and nuclei and developmentally regulated in the hippocampus. Using Cre-mediated mechanisms, we deleted CDKL5 from excitatory CaMKIIα-positive neurons or inhibitory GABAergic neurons. Our data indicate that loss of CDKL5 in excitatory neurons of the cortex or inhibitory neurons of the striatum differentially alters expression of some components of the mechanistic target of rapamycin (mTOR) signaling pathway. Further loss of CDKL5 in excitatory neurons of the cortex or inhibitory neurons of the striatum leads to alterations in levels of synaptic markers in a neuron-type specific manner. Taken together, these data support a model in which loss of CDKL5 alters mTOR signaling and synaptic compositions in a neuron-type specific manner and suggest that CDKL5 may have distinct functional roles related to cellular signaling in excitatory and inhibitory neurons. Thus, these studies provide new insights into the biology of CDKL5 and suggest that the molecular pathology in CDKL5 disorder may have distinct neuron-type specific origins and effects.
KeywordsCDKL5 mTOR Synaptic Signaling CDKL5 disorder
Research in the Arikkath Lab has been supported by start-up funds from the Munroe-Meyer Institute and grants from The Nebraska Research Initiative, an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number 5P20GM103471-10, the Nebraska EPSCoR (EPS-1004094), RO3 from the National Institutes of Health (1R03MH110726-01), and the Brain and Behavior Research Foundation (no. 21080). Ethan Schroeder and Li Yuan were partly supported by graduate student fellowships from the University of Nebraska Medical Center and Nicholas DeKorver was supported by a grant from the National Institutes of Health (AG031158). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Compliance with Ethical Standards
All animal experiments were approved by Institutional Animal Care and Use Committee of the University of Nebraska Medical Center.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 3.Kilstrup-Nielsen C, Rusconi L, La Montanara P, Ciceri D, Bergo A, Bedogni F, Landsberger N (2012) What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy. Neural Plast 2012:728267–728211. https://doi.org/10.1155/2012/728267 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.La Montanara P, Rusconi L, Locarno A, Forti L, Barbiero I, Tramarin M, Chandola C, Kilstrup-Nielsen C et al (2015) Synaptic synthesis, dephosphorylation, and degradation: a novel paradigm for an activity-dependent neuronal control of CDKL5. J Biol Chem 290(7):4512–4527. https://doi.org/10.1074/jbc.M114.589762 CrossRefPubMedGoogle Scholar
- 5.Ricciardi S, Ungaro F, Hambrock M, Rademacher N, Stefanelli G, Brambilla D, Sessa A, Magagnotti C et al (2012) CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat Cell Biol 14(9):911–923. https://doi.org/10.1038/ncb2566 CrossRefPubMedGoogle Scholar
- 6.Zhu YC, Li D, Wang L, Lu B, Zheng J, Zhao SL, Zeng R, Xiong ZQ (2013) Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development. Proc Natl Acad Sci U S A 110(22):9118–9123. https://doi.org/10.1073/pnas.1300003110 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Okuda K, Kobayashi S, Fukaya M, Watanabe A, Murakami T, Hagiwara M, Sato T, Ueno H et al (2017) CDKL5 controls postsynaptic localization of GluN2B-containing NMDA receptors in the hippocampus and regulates seizure susceptibility. Neurobiol Dis 106:158–170. https://doi.org/10.1016/j.nbd.2017.07.002 CrossRefPubMedGoogle Scholar
- 8.Tramarin M, Rusconi L, Pizzamiglio L, Barbiero I, Peroni D, Scaramuzza L, Guilliams T, Cavalla D et al (2018) The antidepressant tianeptine reverts synaptic AMPA receptor defects caused by deficiency of CDKL5. Hum Mol Genet 27(12):2052–2063. https://doi.org/10.1093/hmg/ddy108 CrossRefPubMedGoogle Scholar
- 10.Barbiero I, Peroni D, Tramarin M, Chandola C, Rusconi L, Landsberger N, Kilstrup-Nielsen C (2017) The neurosteroid pregnenolone reverts microtubule derangement induced by the loss of a functional CDKL5-IQGAP1 complex. Hum Mol Genet 26(18):3520–3530. https://doi.org/10.1093/hmg/ddx237 CrossRefPubMedGoogle Scholar
- 12.Pizzo R, Gurgone A, Castroflorio E, Amendola E, Gross C, Sassoe-Pognetto M, Giustetto M (2016) Lack of Cdkl5 disrupts the organization of excitatory and inhibitory synapses and parvalbumin interneurons in the primary visual cortex. Front Cell Neurosci 10:261. https://doi.org/10.3389/fncel.2016.00261 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Della Sala G, Putignano E, Chelini G, Melani R, Calcagno E, Michele Ratto G, Amendola E, Gross CT et al (2016) Dendritic spine instability in a mouse model of CDKL5 disorder is rescued by insulin-like growth factor 1. Biol Psychiatry 80(4):302–311. https://doi.org/10.1016/j.biopsych.2015.08.028 CrossRefPubMedGoogle Scholar
- 14.Fuchs C, Trazzi S, Torricella R, Viggiano R, De Franceschi M, Amendola E, Gross C, Calza L et al (2014) Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3beta signaling. Neurobiol Dis 70:53–68. https://doi.org/10.1016/j.nbd.2014.06.006 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Wang IT, Allen M, Goffin D, Zhu X, Fairless AH, Brodkin ES, Siegel SJ, Marsh ED et al (2012) Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc Natl Acad Sci U S A 109(52):21516–21521. https://doi.org/10.1073/pnas.1216988110 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Tang S, Wang IJ, Yue C, Takano H, Terzic B, Pance K, Lee JY, Cui Y et al (2017) Loss of CDKL5 in glutamatergic neurons disrupts hippocampal microcircuitry and leads to memory impairment in mice. J Neurosci 37(31):7420–7437. https://doi.org/10.1523/JNEUROSCI.0539-17.2017 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Yuskaitis CJ, Jones BM, Wolfson RL, Super CE, Dhamne SC, Rotenberg A, Sabatini DM, Sahin M et al (2018) A mouse model of DEPDC5-related epilepsy: neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility. Neurobiol Dis 111:91–101. https://doi.org/10.1016/j.nbd.2017.12.010 CrossRefPubMedGoogle Scholar
- 25.Gertsenstein M, Nutter LM, Reid T, Pereira M, Stanford WL, Rossant J, Nagy A (2010) Efficient generation of germ line transmitting chimeras from C57BL/6N ES cells by aggregation with outbred host embryos. PLoS One 5(6):e11260. https://doi.org/10.1371/journal.pone.0011260 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Borrie SC, Brems H, Legius E, Bagni C (2017) Cognitive dysfunctions in intellectual disabilities: the contributions of the Ras-MAPK and PI3K-AKT-mTOR pathways. Annu Rev Genomics Hum Genet 18:115–142. https://doi.org/10.1146/annurev-genom-091416-035332 CrossRefPubMedGoogle Scholar
- 34.Rusconi L, Kilstrup-Nielsen C, Landsberger N (2011) Extrasynaptic N-methyl-D-aspartate (NMDA) receptor stimulation induces cytoplasmic translocation of the CDKL5 kinase and its proteasomal degradation. J Biol Chem 286(42):36550–36558. https://doi.org/10.1074/jbc.M111.235630 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Mari F, Azimonti S, Bertani I, Bolognese F, Colombo E, Caselli R, Scala E, Longo I et al (2005) CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet 14(14):1935–1946. https://doi.org/10.1093/hmg/ddi198 CrossRefPubMedGoogle Scholar
- 37.Sekiguchi M, Katayama S, Hatano N, Shigeri Y, Sueyoshi N, Kameshita I (2013) Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder. Arch Biochem Biophys 535(2):257–267. https://doi.org/10.1016/j.abb.2013.04.012 CrossRefPubMedGoogle Scholar
- 38.Switon K, Kotulska K, Janusz-Kaminska A, Zmorzynska J, Jaworski J (2017) Molecular neurobiology of mTOR. Neuroscience 341:112–153. https://doi.org/10.1016/j.neuroscience.2016.11.017 CrossRefPubMedGoogle Scholar
- 40.Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, Murphy JP, Pierre P, Klann E (2012) Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76(2):325–337. https://doi.org/10.1016/j.neuron.2012.07.022 CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Fuchs C, Gennaccaro L, Trazzi S, Bastianini S, Bettini S, Martire VL, Ren E, Medici G et al (2018) Heterozygous CDKL5 knockout female mice are a valuable animal model for CDKL5 disorder. Neural Plast 2018:9726950–9726918. https://doi.org/10.1155/2018/9726950 CrossRefPubMedPubMedCentralGoogle Scholar